Changes in serum adipocyte fatty acid‐binding protein in women with gestational diabetes mellitus and normal pregnant women during mid‐ and late pregnancy

Zhang, Ying; Zhang, Hao‐hang; Lü, Jing; Zheng, Siyuan; Long, Tao; Li, Yingtao; Wu, Wei; Wang, Fang

doi:10.1111/jdi.12484

Cited by 50 publications

(64 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Also, Zhang et al (40) detected higher level of AFABP during mid-and late stages of pregnancy in GDM women and concluded that AFABP might be closely related to obesity and IR in pregnancy, and is a major risk factor for GDM. Thereafter, Li et al (41) detected significantly higher expression of AFABP in serum, placenta and decidua of pregnant GDM women than in normal pregnant women.…”

Section: Discussion:-mentioning

confidence: 99%

Serum Adropin and Adipose Fatty-Acid Binding Protein at 6th Week of Pregnancy Are Significant Predictors for Development of Insulin Resistance at the 24th Week.

Sharafeldeen¹

2018

IJAR

View full text Add to dashboard Cite

Section: Discussion:-mentioning

confidence: 99%

Serum Adropin and Adipose Fatty-Acid Binding Protein at 6th Week of Pregnancy Are Significant Predictors for Development of Insulin Resistance at the 24th Week.

Sharafeldeen¹

2018

IJAR

View full text Add to dashboard Cite

“…In contrast with other adipokines, such as retinol-binding protein 4 (RBP-4) and visfatin, adiponectin is inversely correlated to type 2 diabetes mellitus and GDM [12][13][14] . However, fewer studies show that low adiponectin levels have no association with the risk of GDM 15,16 .…”

Section: Introductionmentioning

confidence: 99%

Ficolin‐3/adiponectin ratio for the prediction of gestational diabetes mellitus in pregnant women

Yuan

Shi

Wang

et al. 2017

J of Diabetes Invest

View full text Add to dashboard Cite

Aims/IntroductionTo establish that the ficolin‐3/adiponectin ratio is a predictor for gestational diabetes mellitus (GDM) and is eligible for screening tests for GDM.Materials and MethodsA prospective cohort study of 86 pregnant women who developed GDM and 273 normal glucose tolerance participants was carried out. Maternal serum ficolin‐3, adiponectin levels were investigated at 16–18 weeks of gestation using enzyme‐linked immunosorbent assay.ResultsCompared with the normal glucose tolerance group, the GDM group showed significantly higher levels of ficolin‐3 and the ratio of ficolin‐3/adiponectin; and decreased levels of adiponectin between 16–18 weeks of gestation (P < 0.05 or P < 0.01). The cut‐off values for the ratio of ficolin‐3/adiponectin (≥1.06; sensitivity 90.9%, specificity 96.5%) to discriminate the pregnant women who developed GDM from the non‐diabetic cases were identified using receiver operating characteristic analysis. Using binary logistic regression analysis, ficolin‐3, retinol‐binding protein‐4 and adiponectin, but not C‐reactive protein, triglyceride and free fatty acids were shown as predictive factors for GDM.ConclusionsThe ratio of ficolin‐3/adiponectin at 16–18 weeks of gestation was changed in pregnant women who subsequently developed GDM, and might provide effective early predicting and screening for GDM.

show abstract

“…GDM generally results in few symptoms; however, it does in- Du crease the risk of macrosomia, preeclampsia, and perinatal death [3]. Good control of blood glucose during pregnancy may contribute to prevent the occurrence of negative gestational complications and a good feral outcome in women with GDM in the short run [4].…”

Section: Introductionmentioning

confidence: 99%

A Prospective Study of Maternal Plasma Concentrations of Retinol-Binding Protein 4 and Risk of Gestational Diabetes Mellitus

Du¹,

Kong²

2018

Ann Nutr Metab

View full text Add to dashboard Cite

Background: The aim of this study was to investigate whether retinol-binding protein 4 (RBP4) concentrations, measured at the first prenatal visit, are associated with risk of gestational diabetes mellitus (GDM). Methods: From July 2015 to June 2016, consecutive women who admitted to the obstetrics center of our hospital were included. At the first prenatal visit (the median gestational age was 6 [interquartile range 4–10] weeks) in the hospital, involved subjects were tested for fasting plasma glucose (FPG) and RBP4 using venous plasma samples collected after at least 8 h of fasting in the morning. Data for FPG and RBP4 concentrations at the first prenatal visit and one-step GDM screening with 75-g oral glucose tolerance test performed between 24 and 28 weeks of gestation were collected and analyzed. Results: Blood at first prenatal visit was available for 827 women, among whom GDM developed in 101 (12.2%). In multivariate models comparing the second (Q2), third, and fourth quartiles against the first quartile of RBP4, concentrations of RBP4 in Q2, Q3, and Q4 were associated with GDM later developed, and increased risk of GDM by 54, 205, and 536%. There was a significant statistical difference in the area under the curve between the established risk factors alone and the addition of RBP4 concentrations (difference, 0.039 [95% CI 0.030–0.052]; p = 0.03). In the subgroup of women combined with obesity and FABP4 ≥median, the measured OR was 9.83 (95% CI [4.76–16.13]; p < 0.001) for GDM compared to those without obesity and FABP4

show abstract

Changes in serum adipocyte fatty acid‐binding protein in women with gestational diabetes mellitus and normal pregnant women during mid‐ and late pregnancy

Cited by 50 publications

References 31 publications

Serum Adropin and Adipose Fatty-Acid Binding Protein at 6th Week of Pregnancy Are Significant Predictors for Development of Insulin Resistance at the 24th Week.

Serum Adropin and Adipose Fatty-Acid Binding Protein at 6th Week of Pregnancy Are Significant Predictors for Development of Insulin Resistance at the 24th Week.

Ficolin‐3/adiponectin ratio for the prediction of gestational diabetes mellitus in pregnant women

A Prospective Study of Maternal Plasma Concentrations of Retinol-Binding Protein 4 and Risk of Gestational Diabetes Mellitus

Contact Info

Product

Resources

About